Artificial intelligence tools in the medical field, OpenEvidence, recently announced a $200 million funding round, bringing its valuation to $6 billion. This round of financing followed a $210 million funding round three months ago, when OpenEvidence increased its valuation to $3.5 billion, showing investors' strong interest in industry-specific AI applications.
Image Source Note: The image is AI-generated, and the image licensing service is Midjourney
OpenEvidence was founded in 2022 with the aim of providing doctors and nurses with a solution for quickly accessing medical knowledge. The platform has been trained on content from medical journals such as the Journal of the American Medical Association and the New England Journal of Medicine, helping healthcare professionals quickly obtain the information they need when treating patients. Currently, verified healthcare professionals can use OpenEvidence's tools for free, and the platform generates revenue through advertising.
Since its founding, OpenEvidence has experienced remarkable growth. Since July of this year, the number of monthly clinical consultations on the platform has nearly doubled, reaching 15 million. This indicates that the demand for this tool among healthcare workers is growing rapidly.
This funding round was led by Google Ventures, with participation from other investment institutions including Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft. These funds will further promote the application and development of OpenEvidence in the medical field.
Key Points:
🌟 OpenEvidence successfully raised $200 million, achieving a valuation of $6 billion, indicating investors' strong interest in medical AI.
📈 Since its establishment in 2022, the platform's monthly clinical consultation volume has reached nearly 15 million, showing rapid demand growth.
💼 This funding round was led by Google Ventures, with participation from several well-known investment institutions, and the funds will help it further develop.
